Currently out of the existing stock ratings of Matt Hewitt, 134 are a BUY (82.72%), 28 are a HOLD (17.28%).

Matt Hewitt

Work Performance Price Targets & Ratings Chart

Analyst Matt Hewitt, currently employed at CRAIG HALLUM, carries an average stock price target met ratio of 49.58% that have a potential upside of 55.25% achieved within 318 days.

Matt Hewitt’s has documented 310 price targets and ratings displayed on 34 stocks. The coverage is on Healthcare, Technology, Consumer Cyclical sectors.

Most recent stock forecast was given on MXCT, MaxCyte at 25-Mar-2026.

Wall Street Analyst Matt Hewitt

Analyst best performing recommendations are on VCRA (VOCERA COMMUNICATIONS).
The best stock recommendation documented was for SLP (SIMULATIONS PLUS) at 11/1/2021. The price target of $53 was fulfilled within 3 days with a profit of $3.98 (8.12%) receiving and performance score of 27.06.

Average potential price target upside

of $46.48 (70.43%) on LGND (LIGAND PHARMACEUTICALS).
of $27.4 (18.23%) on RGEN (REPLIGEN).
of $12.2 (16.45%) on OMCL (OMNICELL).

CDMO Avid Bioservices CDXS Codexis LGND Ligand Pharmaceuticals OMCL Omnicell RGEN Repligen SDGR Schrodinger SRGA Surgalign Holdings TDOC Teladoc TLGT Teligent VCRA Vocera Communications AKRX Akorn APEN Apollo Endosurgery APYX Apyx Medical MDXG MiMedx Group CTEK CynergisTek SLP Simulations Plus TECH Bio-Techne Corp BLFS BioLife Solutions SNCE Science 37 Holdings ANGO AngioDynamics HSTM HealthStream NEO NeoGenomics ACET Adicet Bio AP Ampco-Pittsburgh CD Chindata Group Holdings Ltd CSBR Champions Oncology HAE Haemonetics LFCR Lifecore Biomedical REPH Recro Pharma SRG Seritage Growth Properties VC Visteon Corp LCI Lannett Company ISPC iSpecimen MXCT MaxCyte

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sean Dodge (BMO)